The potency of ensartinib, a novel aminopyridine-based small molecule, is ten times greater than that of crizotinib in inhibiting the growth of ALK-positive lung cancer cell lines and effectively suppressing ALK fusions associated with resistance (Horn et al. 2018; Zhang et al. 2022). Here, ALK is linked to lung cancer.